unveiled a 360-degree view of new age jobs emerging in the pharmaceutical and healthcare sectors, with valuable takeaways for job seekers. Moderated by Mridu Bhandari, Editor – Special Projects ...

The pharmaceutical industry experienced a period ... resulting in bankruptcies, job losses, and depressed valuations. Now, it appears that the malaise is creeping to almost all areas of the ...

What qualifications and experience do you need? And what kind of person thrives in these roles? In this article, we explore 10 of the highest-paying pharma jobs in 2025, detailing their ...

Eli Lilly and Company has announced plans to build four new pharmaceutical sites in the United States, according to a press release from Lilly. The positions are reported to be ‘high-wage.’ The ...

Paired with the current US pharmaceutical job vacancy rate of around 8%, companies will need to pivot to fill the incredible labour needs. So, what are the driving factors for growth in the industry?

Drugmaker Eli Lilly plans to build four new manufacturing plants in the U.S., a $27 billion investment that the company expects will create 3,000 high-skilled jobs and employ 10,000 construction ...

Growers and manufacturers would need to do plenty of groundwork to be able to produce pharmaceutical psilocybin on an industrial, FDA-approved scale. That’s why Optimi is keen to get a head start.

Looking for a new job? These biotech and pharmaceutical companies are growing quickly and offered some of the highest wages in the industry last year. Experts are expecting a wave of job ...

President Donald Trump claimed Ireland has taken advantage of the U.S. and lured its pharmaceutical companies, but said his big beef is with the EU as the threat of a trade war escalates.

This has made for a very tricky job market for recruiters and jobseekers alike, and whilst things are expected to turn around in 2025, they haven’t magically changed since the clock struck midnight on ...

As Bristol Myers Squibb rolls ahead with its plan to cut $1.5 billion in costs by the end of the year, the drugmaker is once ...